NITA DHAKAL POUDYAL: Open Payments
NPI 1033891601 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,536 in 86 payments from 13 companies in 2025. Trend: 2023 $209 · 2024 $1,099 · 2025 $1,536
Food & beverage: $1,536
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 14 | $355 |
| Neurocrine BioSciences, Inc. | 22 | $286 |
| E.R. Squibb & Sons, L.L.C. | 11 | $258 |
| ABBVIE INC. | 12 | $199 |
| Alkermes, Inc. | 9 | $139 |
| Corium, LLC | 9 | $131 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
Products named: HETLIOZ, INGREZZA, COBENFY, VRAYLAR, Azstarys, ARISTADA, CAPLYTA, ABILIFY ASIMTUFII.
Industry payments across IN — which companies pay providers there.
